Preclinical Evaluation of [(155/161)Tb]Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours

Terbium radioisotopes ((149)Tb, (152)Tb, (155)Tb, (161)Tb) offer a unique class of radionuclides which encompass all four medicinally relevant nuclear decay modalities (α, β(+), γ, β(−)/e(−)), and show high potential for the development of element-matched theranostic radiopharmaceuticals. The goal of this study was to design, synthesise, and evaluate the suitability of crown-TATE as a new peptide-conjugate for radiolabelling of [(155)Tb]Tb(3+) and [(161)Tb]Tb(3+), and to assess the imaging and pharmacokinetic properties of each radiotracer in tumour-bearing mice. [(155)Tb]Tb-crown-TATE and [(161)Tb]Tb-crown-TATE were prepared efficiently under mild conditions, and exhibited excellent stability in human serum (>99.5% RCP over 7 days). Longitudinal SPECT/CT images were acquired for (155)Tb- and (161)Tb- labelled crown-TATE in male NRG mice bearing AR42J tumours. The radiotracers, [(155)Tb]Tb-crown-TATE and [(161)Tb]Tb-crown-TATE, showed high tumour targeting (32.6 and 30.0 %ID/g, respectively) and minimal retention in non-target organs at 2.5 h post-administration. Biodistribution studies confirmed the SPECT/CT results, showing high tumour uptake (38.7 ± 8.0 %ID/g and 38.5 ± 3.5 %ID/g, respectively) and favourable tumour-to-background ratios. Blocking studies further confirmed SSTR2-specific tumour accumulation. Overall, these findings suggest that crown-TATE has great potential for element-matched molecular imaging and radionuclide therapy using (155)Tb and (161)Tb.